A method for rapid detection and genotype identification of hepatitis C virus 1–6 by one-step reverse transcription loop-mediated isothermal amplification

Summary

Objective

Hepatitis C virus (HCV) is probably the leading cause of liver cirrhosis and hepatocellular carcinoma globally. Diagnostic tools conventionally used for the detection and identification of HCV infection are technically demanding, time-consuming, and costly for resource-limited environments. This study reports the development of the first rapid loop-mediated reverse transcription isothermal amplification assay that rapidly detects and identifies HCV genotypes in blood components.

Methods

RNA extracted from donor plasma and serum specimens was applied to a one-step reverse transcription loop-mediated isothermal amplification reaction performed with HCV-specific oligonucleotides. Reactions were conducted at 63.5 °C for 30–60 min. The diagnostic characteristics of the assay were investigated and validated with clinical specimens.

Results

Electrophoretic analysis of amplification revealed detection and identification of HCV genotypes 1–6. Positive amplification revealed unique ladder-like banding patterns that identified each HCV genotype. The assay demonstrated a sensitivity of 91.5% and specificity of 100%. Rapid naked-eye detection of HCV infection was facilitated by observation of an intense fluorescent glow of amplified targets under UV illumination. Continue reading…….

Founded in 2015, Shufflex Biomed is headquartered in Germantown, Maryland, about 30 miles from Washington, DC and also based in Lower Johnsonville in Monrovia, Liberia, West Africa.

Pathogens we target

Pathogens Con't

Technologies

Features

Dr. Dougbeh Chris Nyan, M.D.

Inventor, Multiplex Pathogen Diagnostic Test

  • Biomedical research scientist; specializes in infectious disease diagnostics
  • Medical Degree: Charité-Medical Faculty; Humboldt-University of Berlin, Germany
  • Scientist/Fellow: US National Institutes of Health (NIH)
  • Scientist/Fellow: Laboratory of Emerging Pathogens, FDA
  • Scientist: Naval Medical Research Center
  • Scientist: BioReliance, Inc.
  • Research Fellow: University of Pennsylvania School of Medicine
  • Senior Scientist: Nabi Biopharmaceuticals Corp.
  • Testified before the US Congress on September 17, 2014 on the Ebola outbreak
  • Director: Diaspora Ebola Task Force
  • Member: International Society for Infectious Diseases (ISID)
  • Member: The European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
  • Member: Data Safety Monitoring Board (DSMB), US-West African PREVAIL (Vaccine Trails)